Applied Therapeutics Tender Offer Extended; Only 41.29% Shares Tendered So Far

summarizeSummary

Applied Therapeutics' tender offer by Cycle Group Holdings has been extended by one day to January 28, 2026, with only 41.29% of outstanding shares tendered as of the previous deadline, indicating potential challenges in meeting the majority condition.

check_boxKey Events

• Tender Offer Extended

  The expiration date for the tender offer by AT2B, Inc., an indirect wholly owned subsidiary of Cycle Group Holdings Limited, has been extended from January 27, 2026, to January 28, 2026.

• Low Tender Rate Reported

  As of January 27, 2026, approximately 63,684,636 shares, representing only 41.29% of Applied Therapeutics' outstanding shares, have been validly tendered, falling short of the majority condition.

• Acquisition Terms Unchanged

  The offer price remains $0.088 per share in cash plus one non-tradeable contingent value right (CVR), with potential payments up to an aggregate of $0.40 per CVR.

auto_awesomeAnalysis

This amendment provides a critical update on the ongoing tender offer by Cycle Group Holdings for Applied Therapeutics. The one-day extension of the offer, coupled with the disclosure that only 41.29% of shares have been tendered, signals potential difficulties in meeting the majority tender condition required for the acquisition to close. Investors should closely monitor further developments as the low tender rate and short extension suggest the deal's completion is not yet assured, despite the board's prior recommendation.